SCHEMBL30837901

SCHEMBL30837901

COc1cc(Cn2c(=O)c3cc(OC(CF)CF)c(F)cc3n(C3CCN(C=O)CC3)c2=O)ccc1OCc1cccc(O)c1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 10/20 0.66
PDE7B Q9NP56 5/20 0.66
PDE8A O60658 3/20 0.66
CSF1R P07333 1/20 0.37
POLB P06746 2/20 0.37
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136165 1.00 PDE7A (0.66) PDE7APDE7BPDE8ACSF1RPOLB
SCHEMBL100208 0.94 PDE7A (0.66) PDE7APDE7BPDE8ACSF1RPOLB
SCHEMBL101150 0.94 PDE7A (0.70) PDE7APDE7BPDE8ACSF1RNPC1
SCHEMBL30837812 0.93 PDE7A (0.65) PDE7APDE7BPDE8ACSF1RPOLB
SCHEMBL100296 0.93 PDE7A (0.65) PDE7APDE7BPDE8ACSF1RPOLB
SCHEMBL100417 0.92 PDE7A (0.69) PDE7APDE7BPDE8ACSF1RNPC1
SCHEMBL101024 0.92 PDE7A (0.63) PDE7APDE7BPDE8ACSF1R
SCHEMBL101023 0.91 PDE7A (0.70) PDE7APDE7BPDE8ACSF1RSMN1; SMN2
SCHEMBL100517 0.91 PDE7A (0.62) PDE7APDE7BPDE8ACSF1RPOLB
SCHEMBL3756258 0.91 PDE7A (0.64) PDE7APDE7BPDE8ACSF1RPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed